Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Low-dose chemotherapy]

K Ogata1, T Yamada, K Dan

  • 1Third Department of Internal Medicine, Nippon Medical School.

[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology
|September 1, 1996
PubMed
Summary

Low-dose chemotherapy, including cytarabine and etoposide, shows promise for myelodysplastic syndromes (MDS) and refractory acute myeloid leukemia (AML). Responders experienced longer survival, indicating potential as a therapeutic strategy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Measuring and maintaining organ perfusion in a patient with Takayasu's arteritis undergoing cardiac surgery.

Anaesthesia reports·2023
Same author

TdT-Positive, SmIg-Negative B Precursor Cell Leukemia with Burkitt Morphology: A Case Report.

Leukemia & lymphoma·2016
Same author

Screening out the non-Arrhenius behaviour of nematic-isotropic transition by room temperature ionic liquid.

The Journal of chemical physics·2016
Same author

Entropic screening preserves non-equilibrium nature of nematic phase while enthalpic screening destroys it.

The Journal of chemical physics·2016
Same author

Non-equilibrium phase transitions in a liquid crystal.

The Journal of chemical physics·2015
Same author

Inhibition of S100A6 induces GVL effects in MLL/AF4-positive ALL in human PBMC-SCID mice.

Bone marrow transplantation·2014

Area of Science:

  • Hematology
  • Oncology
  • Internal Medicine

Background:

  • Myelodysplastic syndromes (MDS) and refractory acute myeloid leukemia (AML) are hematologic malignancies with limited treatment options.
  • Low-dose chemotherapy represents a potential therapeutic strategy for these conditions.

Purpose of the Study:

  • To evaluate the clinical outcomes of low-dose chemotherapy in patients with MDS and refractory AML.
  • To assess the efficacy of low-dose cytarabine, etoposide, and combination therapy.

Main Methods:

  • Retrospective analysis of 34 MDS patients treated with low-dose cytarabine.
  • Evaluation of 13 MDS patients treated with low-dose etoposide.
  • Analysis of 7 MDS patients receiving combination low-dose cytarabine and etoposide therapy.

Main Results:

  • Complete remission (CR) and partial remission (PR) rates were observed with low-dose cytarabine (32% CR, 18% PR) and etoposide (8% CR, 31% PR).
  • Combination therapy yielded a 29% CR rate.
  • Higher CR rates were noted in MDS patients with Auer bodies in blasts.
  • Responders demonstrated longer overall survival compared to non-responders.

Conclusions:

  • Low-dose chemotherapy is a viable therapeutic strategy for MDS and refractory AML.
  • Further research is warranted to optimize treatment protocols and improve remission rates and duration.

Related Experiment Videos